NCT00876577

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,206 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).

Conditions

• Chronic Bronchitis
• Disease Exacerbation

Interventions

Type	Name	Description
DRUG	Moxifloxacin (Avelox, BAY12-8039)	Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information

Timeline

• Start date: 2009-05-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2009-04-06
• Last updated: 2012-09-10

Locations

1 site across 1 country: China